Abstract: Provided is a composition and a fructose production method, wherein the composition contains: sucrose phosphorylase or a microorganism expressing same; or a culture or lysate of the microorganism whereby fructose can be produced at low cost with high yield.

Abstract: A display apparatus can include a substrate having a penetrating area and a separating area, the penetrating area including a substrate hole, a first buffer layer having a first-buffer lower layer, and a first-buffer upper layer, a first thin film transistor including a first semiconductor pattern, a first gate electrode, and a first source electrode and a first drain electrode, a first interlayer insulating film; a second interlayer insulating film, an opening extending through the second interlayer insulating film, the first interlayer insulating film, the first gate insulating film and the first-buffer upper layer, and a separation structure in the opening, the separation structure including a first separation layer having a same stacked structure as the first-buffer upper layer, a second separation layer having a same stacked structure as the first gate insulating film, and a third separation layer having a same stacked structure as the first gate electrode.

Abstract: The present disclosure relates to a system for controlling a motor of a vehicle for increasing control accuracy of the motor for driving the vehicle, and an object of the present disclosure is to provide a system for controlling a motor of a vehicle, which may accurately perform a motor control even when a battery voltage (i.e., motor voltage) applied to the motor upon the driving control of the motor is changed.

Abstract: Disclosed herein are a neural network model deployment method and apparatus for providing a deep learning service. The neural network model deployment method may include providing a specification wizard to a user, searching for and training a neural network based on a user requirement specification that is input through the specification wizard, generating a neural network template code based on the user requirement specification and the trained neural network, converting the trained neural network into a deployment neural network that is usable in a target device based on the user requirement specification, and deploying the deployment neural network to the target device.

Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.

Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.

Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.

Abstract: The present invention relates to a method for isolation of autologous cancer antigen-specific CD8 T cell by using CD71 and uses thereof. In case of isolating autologous cancer antigen-reactive CD8 T cells using the isolation method of the present invention, it is possible to provide significant anticancer effects by amplifying a large amount of CD8 T cells even with less blood since CD8 T cells responding to various cancer antigens in addition to CD8 T cells specific for autologous cancer antigen are also separated. Therefore, it can be effectively used for immunotherapy that induces temporary immunodeficiency for treatment such as adoptive cell therapy.

Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.

Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.

Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.

Abstract: The present invention relates to an anticancer T cell therapy product-assisting composition comprising a depleting anti-CD4 monoclonal antibody and a use thereof. Accordingly, the composition comprising a depleting anti-CD4 monoclonal antibody according to the present invention is able to maximize the anticancer effect of a cancer antigen-specific anticancer T cell therapy product by maintaining an immunodeficient state and is thus effective. In addition, when administered twice or more times at regular intervals of 5 to 8 days, the composition exhibits a far superior effect.

Abstract: Shown are a coffee extraction system and a coffee extraction method using the same.

Abstract: The present invention relates to an immunogenic fragment peptide of an EN2 protein or an antibody composition specifically recognizing the same. In the present invention, EN2 protein can be quantified through a method of specifically recognizing the peptide. Also, an antibody prepared using the peptide has vastly superior detection sensitivity compared to existing EN2 protein antibodies and thus can be useful in a diagnostic agent for diagnosing prostate cancer.

Abstract: Disclosed are a coffee extraction system and a coffee extraction method using the same.

Abstract: The present invention relates to a composition for preventing or treating neurological diseases including an extract of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient. The composition of the present disclosure has a superior effect of inhibiting the activity of acetylcholinesterase (AChE), which hydrolyzes the neurotransmitter acetylcholine directly involved in impairment of cognitive function. In addition, the composition of the present disclosure is safe for the human body since the biologically safe extract of Euphoria longan fruit, red sage and Gastrodia elata is used as the active ingredient.

Abstract: A use of vivapain-4 (VX-4), which is a cysteine protease of Plasmodium vivax, showing pH-dependent switching of substrate specificity, is provided. More specifically, a method of treating a parasitic disease caused by Plasmodium vivax by inhibiting VX-4; a method of screening a protease inhibitor acting on VX-4, wherein the protease inhibitor is useful as an anti-malarial agent acting on Plasmodium species, for example, Plasmodium vivax; and a method of identifying the activity of VX-4, are provided.

Abstract: A display apparatus and a method of manufacturing the same includes a substrate including a plurality of organic layers and a plurality of inorganic layers, a display unit formed on the substrate and an encapsulation unit formed on the display, wherein the plurality of organic layers and the plurality of inorganic layers comprise at least a first organic layer, a first inorganic layer, a second organic layer, and a second inorganic layer which are sequentially stacked, and wherein an interfacial adhesion strength of the second organic layer is higher than an interfacial adhesion strength of the first organic layer.

Abstract: A use of vivapain-4 (VX-4), which is a cysteine protease of Plasmodium vivax, showing pH-dependent switching of substrate specificity, is provided. More specifically, a method of treating a parasitic disease caused by Plasmodium vivax by inhibiting VX-4; a method of screening a protease inhibitor acting on VX-4, wherein the protease inhibitor is useful as an anti-malarial agent acting on Plasmodium species, for example, Plasmodium vivax; and a method of identifying the activity of VX-4, are provided.

Abstract: An organic light-emitting display apparatus includes a substrate, a display disposed on the substrate, an opposite substrate disposed to face the substrate with the display therebetween, a seal disposed between the substrate and the opposite substrate to couple the substrate to the opposite substrate and arranged around an outer circumference of the display such that the display is located inside the seal, and a support disposed between the substrate and the opposite substrate and arranged around a corner of the seal so that the corner of the seal is located inside the support.